Radiopharm Theranostics Limited - Sponsored ADR (RADX) vs TScan Therapeutics, Inc. (TCRX)

Radiopharm Theranostics Limited - Sponsored ADR and TScan Therapeutics, Inc. are both Biotechnology companies. Radiopharm Theranostics Limited - Sponsored ADR and TScan Therapeutics, Inc. are of similar size ($24.7M and $23.7M). Across the 9 metrics below, Radiopharm Theranostics Limited - Sponsored ADR leads on 7 and TScan Therapeutics, Inc. on 2.

Valuation

Metric RADX TCRX Biotechnology median
P/E — n/m 7.88
P/S — 6.21 11.47
P/B n/m 0.64 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 0.20 0.74
EV/Sales n/m (3.26) 10.73
Earnings yield — (267.65%) (28.84%)
Free cash flow yield 0.00% (268.00%) (23.03%)

Profitability

Metric RADX TCRX Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin — (1,695.15%) 0.00%
Net margin — (1,655.35%) 0.00%
Free cash flow margin 0.00% (1,665.18%) 0.00%
Return on equity 0.00% (95.80%) (57.72%)
Return on assets 0.00% (50.09%) (49.22%)
Return on invested capital 0.00% (4,588.23%) 0.00%

Growth

Metric RADX TCRX Biotechnology median
Revenue growth (TTM) — 2.15% 5.64%
EPS growth (last fiscal year) (1.97%) 12.28% —
Revenue growth, 5-year CAGR — 56.92% 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric RADX TCRX Biotechnology median
Debt to equity 0.00 0.47 0.00
Current ratio 1.16 3.37 4.73
Net debt to EBITDA 0.07 0.90 0.96

Dividend

Metric RADX TCRX Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric RADX TCRX Biotechnology median
Market cap 24.68m 23.65m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack